Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurothera LabsTSXV:NTLX +12.07%31 FCF Yield % is -0.24 as of Aug. 12, 2026. GuruFocus rates TSXV:NTLX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,004 Drug Manufacturers companies, Neurothera Labs ranks worse than 57.77% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Neurothera Labs FCF Yield % Related Terms
Neurothera Labs FCF Yield % Historical Data
* Premium members only.
The historical data trend for Neurothera Labs's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:NTLX vs LLY, JNJ, ABBV: FCF Yield % Comparison
For the Drug Manufacturers - General subindustry, Neurothera Labs's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurothera Labs FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Neurothera Labs's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurothera Labs (TSXV:NTLX) has a FCF Yield % of -0.24 as of Aug. 12, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Neurothera Labs and its competitors. According to the industry distribution chart, Neurothera Labs ranks #580 out of 1004 companies in the Drug Manufacturers industry, placing it in the top 57.8%.
Is Neurothera Labs' FCF Yield % too high?
Neurothera Labs' current FCF Yield % is -0.24. Based on the distribution chart, Neurothera Labs ranks #580 out of 1004 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Neurothera Labs has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' FCF Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Neurothera Labs ranks #580 out of 1004 companies for FCF Yield %. This places Neurothera Labs in the lower half of its industry. The industry median FCF Yield % is 0.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.66, based on 1,004 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Neurothera Labs and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurothera Labs's current FCF Yield % is -0.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (TSXV:NTLX) has a current FCF Yield % of -0.24. The current FCF Yield % is -0.24. Neurothera Labs' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Neurothera Labs (TSXV:NTLX), the current FCF Yield % is -0.24 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
31GF Score
Get the complete analysis for TSXV:NTLX
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NTLX has been successfully added to your 
